Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 838 participants.

Also called NCT02278341

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 838 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02278341
  • EudraCT 2013-001497-16
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Bulgaria, Croatia, Czechia, France, Georgia, Germany, Hungary, Italy, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02278341. Randomized; no masking; primary purpose treatment. Start 2014-11-21 (actual); primary completion 2017-06-08 (actual). Results posted on 2020-08-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Acronym
Pyrenees
Condition
Anemia
Condition
End Stage Renal Disease (ESRD)
Intervention (Drug)
Roxadustat
Intervention (Drug)
Epoetin alfa
Intervention (Drug)
Darbepoetin alfa
Intervention (Drug)
Iron
Lead sponsor
Astellas Pharma Europe B.V. (class: industry)
Collaborator
Kyntra Bio (class: industry)

Record details

Record id
cardio:ct-nct02278341
Content hash
f3b8781394191346d4166a030c1089d140ed90deea44fc56a406070f615f62ce